华蟾素胶囊治疗肿瘤患者顽固性呃逆的临床观察

Clinical Observation of Cinobufacini Capsule in the Treatment of Intractable Hiccup

目的:观察华蟾素胶囊治疗肿瘤患者顽固性呃逆的临床疗效和安全性。方法:120例顽固性呃逆的肿瘤患者按随机数字表法分为观察组(60例)和对照组(60例)。对照组患者给予治疗原发疾病、按压眶上神经等常规治疗,同时口服甲氧氯普胺片10mg,每日3次;观察组患者在对照组治疗的基础上加服华蟾素胶囊,每次2粒,每日3次。1周为1个疗程,两组均治疗4个疗程。观察两组患者临床疗效、呃逆消失时间、卡氏功能状态(KPS)评分,并用TESS副反应量表评价不良反应发生情况。结果:观察组患者总有效率显著高于对照组,呃逆消失时间显著短于对照组,TESS评分显著低于对照组,差异均有统计学意义(P<0.05)。治疗前,两组患者KPS评分比较差异无统计学意义;治疗后,两组患者KPS评分均显著高于治疗前,且观察组显著高于对照组,差异有统计学意义(P<0.05)。结论:华蟾素胶囊治疗肿瘤患者顽固性呃逆疗效较好,可以缩短呃逆持续时间,且安全性较好。

OBJECTIVE:To observe the clinical efficacy and safety of Cinobufacini capsule in the treatment of tumor patientswith intractable hiccup. METHODS:120 tumor patients with intractable hiccup were randomly divided into observation group(60cases)and control group(60 cases)according to the random number table. Control group received conventional treatment,treatmentof primary disease,and the basic treatment of Methoxy metoclopramide tablets 10 mg,tid and intraorbital pressure on neuralnetwork method;observation group additionally received Cinobufacini capsule,2 capsules once,3 times a day. 1-week was regardedas a treatment course,and it lasted 4 courses. Clinical efficacy,Karnofsky functional status(KPS)score and disappearance timeof hiccup were observed,and the incidence of adverse reactions was evaluated by TESS scale. RESULTS:After treatment,the totaleffective rate in observation group was significantly higher than control group,the disappearance time of hiccup and TESS scorewere significantly shorter than control group,the differences were statistically significant(P<0.05). Before treatment,there was nosignificant difference in the KPS score;after treatment,the KPS score in 2 groups was significant higher than before,and observationgroup was higher than control group,the difference was statistically significant(P<0.05). CONCLUSIONS:Both efficacy andsafety of Cinobufacini capsule in the treatment of intractable hiccup are good,and it can shorten hiccup duration.